Darmon A, Ducrocq G, Jasilek A, et al. - Given that low‐dose rivaroxaban and aspirin vs aspirin alone afforded a reduction of ischemic events, at the expense of increased bleeding, in chronic coronary syndromes in the COMPASS trial, researchers herein analyzed COMPASS‐eligible patients to determine whether patients with a favorable trade‐off between ischemic and bleeding events could be detected using the CHA₂DS₂VaSc Score, REACH Recurrent Ischemic (RIS), and REACH Bleeding Risk Score. There were 5.142 patients with ischemic and bleeding outcome of 2.3 (2.1–2.5) and 0.5 (0.4–0.6) per 100 patient‐years, respectively, in the COMPASS‐eligible population. Experts found that identification of potential optimal candidates for adjunction of low‐dose rivaroxaban was enabled by intermediate REACH RIS while patients who exhibited low CHA₂DS₂VaSc score seemed unlikely to benefit from the COMPASS regimen. Serious bleeding occurrence was not predicted by any of these three risk scores.